Pfizer’s Chantix Launch Priority Is Managing Expectations, McKinnell Says
Managing expectations about the effectiveness of Pfizer's smoking cessation therapy Chantix at launch will be vital to the long-term success of the compound, CEO Hank McKinnell said
You may also be interested in...
FDA's approved labeling for GlaxoSmithKline's first-in-class nonprescription weight-loss drug alli (orlistat 60 mg) emphasizes a "goal oriented" indication as opposed to a six-month duration of use as originally proposed
Exubera goes to primary care in 2007: Pfizer will roll out its inhaled insulin Exubera to general practitioners starting in January, the company said; patient and physician education programs limited to endocrinologists began in July (1"The Pink Sheet" July 24, 2006, p. 3). Compensation for sales reps will also change in January: Reps "were incentivized to educate rather than drive volume," Pfizer Head of U.S. Pharmaceutical Operations Peter Brandt said Oct. 19 during the firm's third quarter earnings call. "We are going to be driving more of the volume out of the next wave of our rollout going to the GP community"...
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said